Shannon Lentz
Overview
Companies and innovators looking for creative solutions to complex intellectual property issues trust Shannon Lentz to think outside the box. Whether it is looking for ways to challenge or defend existing patents, or procuring new ones, Shannon has helped craft strategies that mitigate risk and maximize return on intellectual property investments.
Career & Education
- University of Maryland School of Law, J.D.
- University of Maryland, College Park, B.S., molecular biology and genetics
- District of Columbia
- Maryland
- U.S. Patent and Trademark Office (USPTO)
Shannon's Insights
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
Client Alert | 4 min read | 03.11.25
Client Alert | 2 min read | 01.11.24
Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen
Press Coverage | 01.04.24
Crowell IP Powerhouse Rea Leaves Legacy Of Women Leaders At Firm
Representative Matters
- Representing LifeNet Health in a five-patent case against Surgalign (f/k/a RTI Surgical) involving soft tissue grafts and spinal implants, successfully defending LifeNet Health’s patents against IPR petitions filed by Surgalign.
- Represented inventors in a highly contested patent inventorship bench trial in the Central District of California and subsequent appeal to the Federal Circuit involving a pharmaceutical compound.
- Moderna v. CureVac: Represented patent owner CureVac in inter partes review before the PTAB relating to purification of RNA.
- Apotex v. Amgen, IPR2016-01542 (PTAB): Represented petitioner Apotex in an inter partes review successfully invalidating a patent relating to Neupogen® and Neulasta®.
- LifeNet Health v. Life Cell Corp., No. 2:13-cv-00486 (E.D. Virginia): Represented plaintiff LifeNet in patent-infringement action involving soft-tissue grafts. Jury awarded LifeNet over $34 million; decision affirmed on appeal.
- Represented university system in patent license dispute over cancer treatment in which the plaintiff pharmaceutical company sought damages exceeding $200 million. Obtained summary adjudication in favor of client.
- Secured a significant victory (a preliminary injunction against patent infringement through trial) on behalf of Lonza Walkersville, Inc. against Israel-based Adva Biotechnology Ltd. in a case involving point-of-care cell-therapy technology.
Shannon's Insights
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
Client Alert | 4 min read | 03.11.25
Client Alert | 2 min read | 01.11.24
Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen
Press Coverage | 01.04.24
Crowell IP Powerhouse Rea Leaves Legacy Of Women Leaders At Firm
Insights
Shannon's Insights
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
Client Alert | 4 min read | 03.11.25
Client Alert | 2 min read | 01.11.24
Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen
Press Coverage | 01.04.24
Crowell IP Powerhouse Rea Leaves Legacy Of Women Leaders At Firm
